Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export

Therapeutic monoclonal antibodies against the PD-L1/PD-1 (programmed death ligand-1/programmed cell death protein-1) axis have achieved great successes in cancer treatments, but the development of small-molecule immunomodulators of the pathway has lagged far behind. We established a cellular cocultu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Fang-Fang, Li, Zheng, Ma, Dawei, Yu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567511/
https://www.ncbi.nlm.nih.gov/pubmed/33110706
http://dx.doi.org/10.1080/2162402X.2020.1831153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567511/
https://www.ncbi.nlm.nih.gov/pubmed/33110706
http://dx.doi.org/10.1080/2162402X.2020.1831153

Ejemplares similares